Loading...
OTCM
BAYRY
Market cap55bUSD
Sep 17, Last price  
14.13USD
1D
0.57%
1Q
33.78%
Jan 2017
-45.80%
Name

Bayer AG

Chart & performance

D1W1MN
OTCM:BAYRY chart
P/E
P/S
1.06
EPS
Div yield, %
0.22%
Shrs. gr., 5y
Rev. gr., 5y
1.94%
Revenues
45.58b
-2.21%
28,956,000,00032,385,000,00032,918,000,00031,168,000,00035,088,000,00036,528,000,00039,741,000,00040,157,000,00041,339,000,00046,085,000,00034,943,000,00035,015,000,00036,742,000,00043,545,000,00041,400,000,00044,081,000,00050,739,000,00047,637,000,00046,606,000,00045,575,000,000
Net income
-3.62b
L+41.85%
1,514,000,0002,301,000,0001,715,000,0001,359,000,0001,301,000,0002,470,000,0002,403,000,0003,189,000,0003,426,000,0004,110,000,0004,531,000,0007,336,000,0001,695,000,0004,091,000,000-10,495,000,0001,000,000,0004,150,000,000-2,941,000,000-2,552,000,000-3,620,000,000
CFO
4.57b
-37.96%
4,202,906,4304,283,000,0003,608,000,0005,375,000,0005,773,000,0005,060,000,0004,532,000,0005,171,000,0005,810,000,0006,890,000,0009,089,000,0008,134,000,0007,917,000,0008,207,000,0004,903,000,0005,089,000,0007,093,000,0005,117,000,0007,368,000,0004,571,000,000
Dividend
Apr 28, 20260.032098 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.

Related entities

Subsidiaries (114)
BAYER NEW ZEALAND LIMITED
Bayer Nordic SE
BAYER NORWAY AS
Bayer Oy
Bayer Pharma Aktiengesellschaft
Bayer Pharmaceuticals Private Limited
Bayer Philippines, Inc.
BAYER PUBLIC LIMITED COMPANY
Bayer Puerto Rico, Inc.
BAYER RESEARCH AND DEVELOPMENT SERVICES LLC
Bayer S A
Bayer S.A.
BAYER S.P.A.
BAYER SAS
Bayer Schering Pharma GmbH
Bayer Science and Innovation Private Limited
Bayer Seeds B.V.
BAYER SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
Bayer Turk Kimya Sanayii Limited Sirketi
BAYER U.S. LLC

Key people

Werner Baumann
Chairman of the Management Board, Chief Executive Officer · since 2016
Thomas de Win
Vice Chairman of the Supervisory Board · since 2006
Johannes M. Dietsch
Chief Financial Officer, Member of the Management Board · since 2014
Independent Member of the Supervisory Board · since 2014
Robert Gundlach
Independent Member of the Supervisory Board, Employee Representative · since 2019
Sabine Schaab
Independent Member of the Supervisory Board, Employee Representative · since 2017
Independent Member of the Supervisory Board · since 2018
IPO date
Nov 28, 1997
Employees
102,048
Domiciled in
DE
Incorporated in
DE
Headquarters & legal address
Kaiser-Wilhelm-Allee 1
Leverkusen, NW 51373
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT